CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genesis Research and Development Corporation Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genesis Research and Development Corporation Limited
P.O. Box 50
Shortland Street
Phone: +64 93735600p:+64 93735600 Auckland, AUC  1140  New Zealand Fax: +64 93735601f:+64 93735601

Filed for Bankruptcy on 11/13/2012
The Company was placed into voluntary liquidation because of "insufficient funds".
This company is no longer actively traded on any major stock exchange.

Business Summary
Genesis Research and Development Corporation Limited, formerly Genesis Research & Development Corp., Ltd. is a biotechnology company, with a primary focus on the development of therapeutics for the treatment of cancer and diseases of the immune system. The company is developing gene silencing technology called RNA interference (RNAi), to target the growth and drug resistance of cancer cells. The aim of the immunology programme is to use antibody-based therapeutics to target Zyrogen, a proprietary growth factor that has been implicated in the development of autoimmune and bone disorders.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201212/31/2011Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Joachim H.von Roy 6/17/2005 6/17/2005
Chief Executive Officer, Company Secretary Stephen G.Hall 12/17/2004 1/1/2003
Director GudeBuer 12/31/2012 12/31/2012
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 140 (As of 6/30/2010)
Outstanding Shares: 45,502,646 (As of 6/30/2012)
Shareholders: 1,997
Stock Exchange: NZE
Fax Number: +64 93735601


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023